Micera
| Mircera® [Pre-filled syringe] |
|
MIS Class : Haematopoietic Agents
Packing/Presentation
| Form |
Packing/Price |
Photo |
| Mircera Pre-filled syringe |
| Mircera 50 mcg/0.3 mL x 1’s |
| Mircera 75 mcg/0.3 mL x 1’s |
| Mircera 100 mcg/0.3 mL x 1’s |
| Mircera 150 mcg/0.3 mL x 1’s |
| Mircera 200 mcg/0.3 mL x 1’s |
| Mircera 250 mcg/0.3 mL x 1’s |
| Mircera 800 mcg/0.6 mL x 1’s |
|
| Mircera vial |
| Mircera 50 mcg x 1’s |
| Mircera 100 mcg x 1’s |
| Mircera 200 mcg x 1’s |
| Mircera 300 mcg x 1’s |
| Mircera 1000 mcg x 1’s |
|
|
|
|
Methoxy polyethylene glycol-epoetin β |
|
Treatment of anaemia associated w/ chronic kidney disease (CKD). |
|
IV/SC Patients currently not treated w/ an erythropoiesis-stimulating agent (ESA) Initially 0.6 mcg/kg body wt once every 2 wk. Patients currently treated w/ an ESA Previous wkly epoetin dose <8,000 iu/wk or darbepoetin α dose <40 mcg/wk Initially 120 mcg/mth. Previous wkly epoetin dose 8,000-16,000 iu/wk or darbepoetin α dose 40-80 mcg/wk Initially 200 mcg/mth. Previous wkly epoetin dose >16,000 iu/wk or darbepoetin α dose >80 mcg/wk Initially 360 mcg/mth. |
|
Uncontrolled HTN. |
|
Pure red cell aplasia (PRCA) caused by anti-erythropoietin Ab. Evaluate Fe status prior to & during therapy. Monitor BP. Patient w/ haemoglobinopathies, seizures, bleeding or platelet >500 x 109/L. Do not use for treatment of anaemia in patient w/ cancer. Hepatic impairment, patient <18 yr. Pregnancy & lactation. |
|
HTN, vascular access thrombosis, headache. |
|
Haematopoietic Agents |
|
B03XA03 – Methoxy polyethylene glycol-epoetin beta ; |
|